Key facts
- This page summarizes Gregory R. Friberg's Form 4 filing for BIOMARIN PHARMACEUTICAL INC (BMRN).
- 1 reported transaction and 0 derivative rows are listed below.
- Accepted by SEC: 11 May 2026, 17:01.
Gregory R. Friberg - 07 May 2026 Form 4 Insider Report for BIOMARIN PHARMACEUTICAL INC (BMRN)
- Reporting relationship
- EVP, Chief R&D Officer
- Issuer ticker
- BMRN
- Reported as of
- 07 May 2026
- Net transaction value
- -$176,682
- SEC form
- 4
- Accepted by SEC
- 11 May 2026, 17:01:13 UTC
- Prior SEC filing
- 18 Mar 2026
- Source filing
- View source filing
- Reporting owner signature
- /s/ Tae Sang Yoo, Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Gregory R. Friberg filed Form 4 for BIOMARIN PHARMACEUTICAL INC (BMRN) on 11 May 2026.
Change
- Previous filing in this sequence was filed on 18 Mar 2026.
- Current net transaction value: -$176,682.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reporting Owners (1)
CIK 0002038768
Primary reporting owner
Friberg Gregory R
- Relationship
- EVP, Chief R&D Officer
- Address
- C/O BIOMARIN PHARMACEUTICAL INC., 770 LINDARO STREET, SAN RAFAEL
- Signature
- /s/ Tae Sang Yoo, Attorney-in-Fact
- Signature date
- 11 May 2026
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
BMRN
transaction
Common Stock
Sale
- Transaction value
- $176,682
- Shares
- -3,281
- Change %
- -6%
- Price
- $53.85
- Shares after
- 51,818
- Date
- 07 May 2026
- Ownership
- Direct
* marks a reported price that did not pass the local price check.